Yuyu Pharma to Cancel Treasury Shares in First Half...Decides to Increase Dividends
Yuyu Pharma announced on March 24 its plan to enhance corporate value by increasing shareholder returns and shareholder value through the cancellation of treasury shares and an increase in dividends.
Exterior view of the headquarters of Yuyu Pharma located in Jecheon City, Chungbuk. Yuyu Pharma
View original imageYuyu Pharma will complete the cancellation of its treasury shares held during the first half of the year, thereby implementing an active shareholder return policy. In addition, the company plans to increase dividends with the goal of maintaining high dividend payouts that are subject to separate taxation. Last year, Yuyu Pharma’s profit dividends amounted to 2.1 billion won, up 10.7% from the previous year, with a dividend payout ratio of 26.2%.
Noyong Park, CEO of Yuyu Pharma, stated, "We decided to cancel treasury shares and increase cash dividends in order to reward the support of shareholders who have trusted and supported the company," adding, "We will continue to pursue management activities that promote coexistence between the company and its shareholders."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In the previous year, Yuyu Pharma recorded consolidated sales of 140.8 billion won, operating profit of 11 billion won, and net profit of 9.1 billion won, achieving solid management results for two consecutive years.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.